Vigilancia Tecnológica

Dendritic polymer?based nanomedicines are constructed for sequential delivery of dasatinib (DAS) and epirubicin (Epi). DAS?containing nanomedicine regulates collagen anabolism and energy metabolism of cancer?associated fibroblasts (CAFs) for extracellular matrix (ECM) regulation, thus facilitating the deep penetration of Epi?containing nanomedicine to potentiate immunogenic cell death. This sequential treatment strategy evokes robust antitumor immune responses to suppress breast cancer progression and metastasis.The dense extracellular matrix (ECM) in solid tumors, contributed by cancer?associated fibroblasts (CAFs), hinders penetration of drugs and diminishes their therapeutic outcomes. A sequential treatment strategy of remodeling the ECM via a CAF modifier (dasatinib, DAS) is proposed to promote penetration of an immunogenic cell death (ICD) inducer (epirubicin, Epi) via apoptotic vesicles, ultimately enhancing the treatment efficacy against breast cancer. Dendritic poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA)?based nanomedicines (poly[OEGMA?Dendron(G2)?Gly?Phe?Leu?Gly?DAS] (P?DAS) and poly[OEGMA?Dendron(G2)?hydrazone?Epi] (P?Epi)) are developed for sequential delivery of DAS and Epi, respectively. P?DAS reprograms CAFs to reduce collagen by downregulating collagen anabolism and energy metabolism, thereby reducing the ECM deposition. The regulated ECM can enhance tumor penetration of P?Epi to strengthen its ICD effect, leading to an amplified antitumor immune response. In breast cancer?bearing mice, this approach alleviates the ECM barrier, resulting in reduced tumor burden and increased cytotoxic T lymphocyte infiltration, and more encouragingly, synergizes effectively with anti?programmed cell death 1 (PD?1) therapy, significantly inhibiting tumor growth and preventing lung metastasis. Furthermore, systemic toxicity is barely detectable after sequential treatment with P?DAS and P?Epi. This approach opens a new avenue for treating desmoplastic tumors by metabolically targeting CAFs to overcome the ECM barrier.